


姓名:	陳三奇	填表日期: (YYYY/MM/DD)	2023/05/02	
單位:	腫瘤醫學部	現職職稱:	主治醫師	
Email:	sunkist.chen37@gmail.com	連絡電話:	02-28757529	
學歷:	臺北醫學大學 醫學系 醫學士			
重要經歷:	<p>現職：2017- 迄今 臺北榮民總醫院 腫瘤醫學部 腫瘤內科 主治醫師</p> <p>- 迄今 國立陽明大學 醫學系 內科學科 講師</p> <p>經歷：- 臺北榮民總醫院 內科部 血液科 主治醫師</p> <p>- 臺北榮民總醫院 內科部 腫瘤科 住院總醫師</p>			
研究方向: (關鍵詞)	肝癌、骨肉瘤、免疫治療、肝癌臨床試驗			
五年內 代表著作:	<ol style="list-style-type: none"> 1. Wen-Chi Wu, Tzu-Yuan Lin, Ming-Huang Chen, Yi-Ping Hung, Chien-An Liu, Rheun-Chuan Lee, Yi-Hsiang Huang, Yee Chao, San-Chi Chen*. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-realworld experience. Invest New Drugs. 2022;10.1007/s10637- 022-01248-0. 2. San-Chi Chen, Yi-Hsiang Huang, Ming-Huang Chen, Yi-Ping Hung, Rheun-Chuan Lee, Yu-Yun Shao, *Yee Chao. Anti-PD-1 combined sorafenib versus anti-PD1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity. 3. LT Chen, E Martinelli, AL Cheng, G Pentheroudakis, S Qin, GS Bhattacharyya, M Ikeda, HY Lim, GF Ho, SP Choo, Z Ren, H Malhotra, M Ueno, BY Ryoo, TC Kiang, D Tai, A Vogel, A Cervantes, SN Lu, CJ Yen, YH Huang, SC Chen, C Hsu, YC Shen, J Taberner, Y Yen, CH Hsu, T Yoshino, JY Douillard. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/ relapsed hepatocellular carcinoma: a TOSESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Annals of oncology, 2020 Mar;31(3):334. 4. Pei-Chang Lee, Yee Chao, Ming-Huang Chen, KengHsin Lan, Chieh-Ju Lee, I-Cheng Lee, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang. Predictors of response and survival in immune checkpoint inhibitor-treated unrespectable hepatocellular Carcinoma. Cancers (Basel). 2020 Jan 11;12(1):182. 5. Chien-Yi Hsu, Yu-Wen Su, San-Chi Chen*. Sick sinus syndrome associated with anti-programmed cell death-1. J Immunother Cancer. 2018 Jul 16;6(1):72 			
究室成員:	研究助理 王柏森			